Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Remibrutinib in Severe Renal Impairment
NCT07032272Phase 1Completed
- Sponsor
- Novartis
- Start
- Jul 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of remibrutinib in autoimmune diseases and chronic inflammatory diseases (2 arms), sponsored by Novartis. Primary endpoints: Maximum steady-state concentration of remibrutinib in blood, Area under the curve over the dosing interval at steady state of remibrutinib in blood and 2 more. Started Jul 2025; status: completed.
02
Drugs
remibrutinib
03
Conditions
autoimmune diseaseschronic inflammatory diseases
Beyond the preview
Go deeper on NCT07032272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07032272.